Growdea Technologies Pvt Ltd

What Growdea Technologies Pvt Ltd does

Growdea Technologies Pvt Ltd is an India-based computational biology company that develops AI-driven in-silico platforms for drug discovery and development. Founded in 2018 at the Indian Institute of Technology (IIT) Delhi, the company combines machine learning with physics-based molecular modeling on GPU-accelerated infrastructure to support pharmaceutical and biotechnology teams across the drug lifecycle. The product portfolio spans six platforms: Analogue, a unified no-code in-silico drug discovery suite covering molecule generation, docking, molecular dynamics, and QSAR modeling; ADMET-Vault and BioTox for early-stage pharmacokinetics and toxicity prediction; INSILICO-BE and BioSim-AI for formulation, bioequivalence, and biosimilar development; and GrowSearch for AI-powered scientific literature discovery using retrieval-augmented generation. ADMET-Vault is publicly validated through top-5 rankings across 12 ADMET properties on the Therapeutics Data Commons leaderboard, and BioTox reports 85%+ prediction accuracy across organ systems.

Name

Growdea Technologies Pvt Ltd

Legal name

Growdea Technologies Pvt Ltd

Website

https://growdeatech.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Growdea Technologies is an IIT Delhi-founded AI company building in-silico drug discovery and development platforms — including Analogue, ADMET-Vault, BioTox, INSILICO-BE, BioSim-AI, and GrowSearch — for pharmaceutical, biotechnology, academic, and government research clients globally.

Ownership category

akta.pro rank

Headquarters

HQ city

New Delhi

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. SaaS Platform Subscriptions: The company offers its AI-powered drug discovery platforms (Analogue, ADMET-Vault, BioTox, INSILICO-BE, BioSim-AI, GrowSearch) as software solutions to pharmaceutical and biotech clients. Given the enterprise sales motion with demo requests, this appears to be a subscription-based or licensing model for platform access.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Growdea Technologies develops and sells AI-driven computational biology platforms for in-silico drug discovery and development. Its product suite spans the drug lifecycle from target identification through biosimilar development, including the Analogue drug discovery suite (molecule generation, docking, GPU-accelerated molecular dynamics, QSAR), ADMET-Vault (pharmacokinetics/toxicity prediction), BioTox (toxicity intelligence), INSILICO-BE (formulation/bioequivalence), BioSim-AI (biosimilar CQA prediction), and GrowSearch (RAG-based literature search). The platforms are delivered as software subscriptions to pharmaceutical, biotechnology, academic, and government research clients.

Product overview

Growdea Technologies offers a unified portfolio of AI-powered in-silico drug discovery and development platforms. The Discovery suite includes Analogue (core molecular simulation and ranking platform), ADMET-Vault (pharmacokinetics and toxicity prediction), and BioTox (clinical toxicity intelligence). The Development suite includes INSILICO-BE (formulation and bioequivalence prediction), BioSim-AI (biosimilar development intelligence), and GrowSearch (scientific knowledge discovery). Analogue itself comprises multiple integrated modules including MoleuGen-Net, Binding-Net, Pharmal-Net, DecoyFinder-Net, Ag-Ab, DockANA, SimANA, Trajecta, FragANA, QSAR, Umbrella Sampling, and REMD. The platforms are built on GPU-accelerated computing and combine AI/ML models with physics-based simulations.

Differentiator

Problem solved

Functional benefit

Brands

• Analogue: AI-driven molecular simulation and ranking platform for in-silico drug discovery, integrating molecule generation, docking, molecular dynamics, and predictive modeling.
• ADMET-Vault
• BioTox
• INSILICO-BE
• BioSim-AI
• GrowSearch

Products and services

• Analogue Unified AI-powered drug discovery platform that integrates AI molecule generation, binding affinity prediction, molecular docking, GPU-accelerated dynamics simulations, and QSAR modeling within a single no-code graphical interface. Built for pharmaceutical and biotechnology discovery teams and academic researchers who need lab-grade candidate ranking without command-line expertise.
• ADMET-Vault Early-stage pharmacokinetics and toxicity prediction platform that uses machine learning to predict ADMET properties before costly experiments, helping pharmaceutical and biotech teams cut late-stage failures and accelerate lead optimization. Trained on verified datasets spanning multiple therapeutic classes with ensemble-Murcko scaffold splits for real-world generalization.
• BioTox AI-powered clinical toxicity and safety intelligence platform that identifies potential safety risks early in drug discovery for small molecules, peptides, and biologics using machine learning trained on human iPSC assays, omics data, and clinical evidence. Enables proactive safety assessment before in-vivo and clinical studies.
• INSILICO-BE AI-driven formulation intelligence platform that enables early-stage in-silico prediction of pharmacokinetics and bioequivalence (Cmax, Tmax, AUC, t1/2) before in-vivo studies, with excipient impact modeling and PBPK-guided physiological accuracy for pharmaceutical formulation teams developing generic drugs.
• BioSim-AI Biological and biosimilar development intelligence platform offering AI-driven critical quality attribute (CQA) prediction, cell culture optimization, glycosylation analysis, and stability modeling aligned with ICH regulatory expectations for biosimilar developers.
• GrowSearch AI-powered scientific knowledge discovery platform combining semantic literature search, conversational AI-based paper exploration, and similarity graph construction for intelligent knowledge discovery across scientific research, enabling contextual question answering beyond keyword matching.

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability14 records

Feature6 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• XtalPi: AI + quantum physics-based drug discovery platform offering crystal structure prediction, molecular generation, and ADMET prediction through SaaS and partnerships. Closely comparable to Growdea's combination of physics-based simulation with ML for pharma clients.
• BenevolentAI: AI drug discovery platform combining knowledge graphs with ML for target identification and drug repurposing. Comparable to Growdea's GrowSearch semantic literature component and broader ML-driven discovery approach.
• ChemAxon: Cheminformatics software provider offering molecule handling, QSAR, ADMET prediction, and visualization tools for pharma R&D. Direct overlap with Growdea's QSAR, ADMET prediction, and molecular analytics functionality.
• Atomwise: AI small-molecule discovery platform using convolutional neural networks for structure-based hit identification across pharma and academic collaborations. Overlaps with Growdea's MoleuGen-Net, Binding-Net, and DockANA capabilities.
• Insilico Medicine: AI-driven drug discovery company combining generative chemistry, target identification, and clinical-stage pipelines using deep learning platforms. Comparable to Growdea in applying AI/ML across the full discovery workflow from target to lead optimization.

Broad incumbents

• Schrödinger, Inc. Public computational chemistry and molecular simulation platform with physics-based and ML-driven drug discovery software used by most major pharma companies. Direct overlap with Growdea's Analogue platform in docking, MD, and binding affinity prediction, though Schrödinger serves a broader enterprise pharma customer base.
• BIOVIA (Dassault Systèmes): Enterprise life sciences software suite covering discovery, biosimilars, formulation, and regulatory submissions within the broader Dassault 3DEXPERIENCE platform. Overlaps with Growdea's discovery-to-biosimilar workflow span at much larger enterprise scale.
• OpenEye Scientific (Cadence Design Systems): Molecular modeling and cheminformatics software platform offering docking, MD, shape-based screening, and ADMET tools widely used in pharma. Comparable to Growdea's Analogue suite on structure-based drug design capabilities.
• Recursion Pharmaceuticals: AI-driven biotech combining high-throughput biology with ML for target identification and lead generation, with own clinical pipeline. Overlaps with Growdea on ADMET/BioTox-style predictive modeling and target prioritization at pharma scale.

Regional players

• Aragen Life Sciences: India-headquartered CRO/CDMO offering computational biology, discovery, and biosimilar development services to global pharma. Comparable as an India-based peer combining AI-driven discovery with downstream biologics/formulation capabilities similar to Growdea's BioSim-AI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/growdea-technologies-pvt-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Growdea Technologies Pvt Ltd